Search results
Results from the WOW.Com Content Network
Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. [5] It is delivered subcutaneously either by injection or from an insulin pump .
Eli Lilly and Company developed and marketed the first rapid-acting insulin analogue (insulin lispro rDNA) Humalog. It was engineered through recombinant DNA technology so that the penultimate lysine and proline residues on the C-terminal end of the B-chain were reversed.
The lower-priced version of Humalog Mix75/25 will be known as Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen (100 units/mL) while that of Humalog Junior KwikPen ...
The shortage applies to the company's 10 mL vials of Humalog and Insulin Lispro Injection medications.
Eli Lilly's (LLY) insulin candidate, Ultra Rapid Lispro, meets primary endpoint of two late- stage studies in type I and type II diabetes patients of non-inferiorly to Humalog.
1983 Eli Lilly and Company produces biosynthetic human insulin with recombinant DNA technology, Humulin; 1985 Axel Ullrich sequences a human cell membrane insulin receptor. 1988 Novo Nordisk produces recombinant biosynthetic human insulin; 1996 Lilly Humalog "lispro" insulin analogue approved.
For premium support please call: 800-290-4726 more ways to reach us
Pages in category "Drugs developed by Eli Lilly and Company" The following 113 pages are in this category, out of 113 total. This list may not reflect recent changes .